As more sophisticated precision medicines come to market, there is an increased need for evidence-based scientific engagement with a rapidly evolving set of stakeholders.
With contributions from European medical leaders from Allergan, Bristol-Myers Squibb, GSK, Johnson & Johnson, Incyte and Kyowa Kiran, this white paper shares insights into how medical affairs can transform into a strategic function that drives the organization to become data-driven and customer-centric.
Learn the role of medical affairs in:
Increasing communication and collaboration with new stakeholders, including patients, providers and payers
Maximizing the impact of scientific engagement with personalized HCP content
Delivering a medical affairs ROI from medical insights, real-world evidence and HEOR data